Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qishe Pill is a compound Traditional Chinese Medicine (TCM) developed by Shanghai Sundise Traditional Chinese Medicine Co., Ltd. and researchers at the Shanghai University of Traditional Chinese Medicine. It is composed of six main ingredients: processed Radix Astragali, Muscone, Szechuan Lovage Rhizome, Radix Stephaniae Tetrandrae, Ovientvine, and Calculus Bovis Artifactus. The formulation is primarily used for the treatment of cervical spondylosis, including cervical radiculopathy and cervical spondylotic myelopathy, to alleviate neck pain and improve postoperative recovery. It has been in clinical use since 2009 and has undergone various clinical trials to evaluate its efficacy and safety compared to standard treatments like mecobalamin or celecoxib.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qishe Pill.